Major R&D Pipeline: 3ADCs
Major R&D Milestones in FY2021 (3ADCs)
As of July 2021
Daiichi-Sankyo
FY2021
Q1
Q2
Q3
Q4
TLR anticipated
TLR anticipated
Study started
TLR obtained
Study started
TLR obtained
Submission anticipated (Europe)
Project
BC
ENHERTUⓇ
GC
NSCLC
Dato-DXd
HER3-DXd
Target Indications [phase, study name]
HER2+, 2L [P3, DESTINY-Breast03]
HER2 low, post chemo [P3, DESTINY-Breast04]
HER2+, 1L [P3, DESTINY-Breast09]
HER2+, 2L [P2, DESTINY-Gastric02]
HER2+, 2L [P3, DESTINY-Gastric04]
HER2+/mutant [P2, DESTINY-Lung01]
HER2+, combination [P1b, DESTINY-Lung03]
TNBC, durvalumab combo [P1b/2, BEGONIA]
EGFR mutated NSCLC, osimertinib combo [P1]
Red underlined: new or updated from FY2020 Q4
BC: breast cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, TLR: Top Line Results, TNBC: triple negative breast cancer
Study started
Study started
Study start
planned
33View entire presentation